# Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

> **NCT05154994** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Utah** · enrollment: 9 (estimated)

## Conditions studied

- Infiltrating Urothelial Carcinoma, Sarcomatoid Variant
- Locally Advanced Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- Unresectable Urothelial Carcinoma

## Interventions

- **DRUG:** Belinostat
- **BIOLOGICAL:** Durvalumab

## Key facts

- **NCT ID:** NCT05154994
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-14
- **Primary completion:** 2026-08
- **Final completion:** 2028-02
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05154994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05154994, "Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT05154994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*